Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer

Kuemmel, Sherko; Heil, Joerg; Bruz̆as, S.; Breit, Elisabeth; Schindowski, D; Harrach, Hakima; Chiari, Ouafaa; Hellerhoff, Karin; Bensmann, E; Hanf, Volker; Graßhoff, Sven-Thomas; Deuschle, P.; Belke, Kerstin; Polata, Silke; Paepke, Stefan; Warm, Mathias; Meiler, Johannes; Schindlbeck, Christian; Ruhwedel, Wencke; Beckmann, Ulrike; Groh, Ulrich; Dall, Peter; Blohmer, Jens‐Uwe; Traut, Alexander; Reinisch, Mattea

doi:10.1001/jamasurg.2023.1772

Public

Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer

Published in JAMA Surgery • Jun 7, 2023

Authors:

Sherko Kuemmel

Joerg Heil

S. Bruz̆as

Abstract

Importance: The increasing use of neoadjuvant systemic therapy (NST) has led to substantial pathological complete response rates in patients with initially node-positive, early breast cancer, thereby questioning the need for axillary lymph node dissection (ALND). Targeted axillary dissection (TAD) i...

Subject

Medicine

Axillary Lymph Node Dissection

Breast cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!